36/120
1.5 / 5 stars
All 120 Win/Lose results shown below
NVAX Roast Me summary
NOVAVAX INC (NVAX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinNVAX / S&P 15.72% / 15.20% |
LoseNVAX / S&P -61.64% / 15.00% |
LoseNVAX / S&P -169.60% / 50.40% |
| 2026-Q11/3 |
WinNVAX / S&P 21.13% / -4.33% |
LoseNVAX / S&P -52.48% / 11.30% |
LoseNVAX / S&P -124.24% / 27.70% |
| 2025-Q41/3 |
LoseNVAX / S&P -22.49% / 2.65% |
WinNVAX / S&P 64.69% / 9.00% |
LoseNVAX / S&P NVAX unavailable / 13.40% |
| 2025-Q32/3 |
WinNVAX / S&P 37.62% / 8.12% |
WinNVAX / S&P 20.27% / 4.61% |
LoseNVAX / S&P NVAX unavailable / 13.45% |
| 2025-Q21/3 |
LoseNVAX / S&P -1.72% / 10.94% |
WinNVAX / S&P 9.22% / 4.83% |
LoseNVAX / S&P NVAX unavailable / 10.63% |
| 2025-Q11/3 |
LoseNVAX / S&P -20.27% / -4.27% |
WinNVAX / S&P 25.92% / 4.98% |
LoseNVAX / S&P NVAX unavailable / 10.57% |
| 2024-Q40/3 |
LoseNVAX / S&P -36.34% / 2.41% |
LoseNVAX / S&P -30.65% / 5.25% |
LoseNVAX / S&P NVAX unavailable / 6.15% |
| 2024-Q30/3 |
LoseNVAX / S&P -0.24% / 5.89% |
LoseNVAX / S&P -15.68% / 5.89% |
LoseNVAX / S&P NVAX unavailable / 6.11% |
| 2024-Q21/3 |
WinNVAX / S&P 164.85% / 4.28% |
LoseNVAX / S&P -38.17% / 5.38% |
LoseNVAX / S&P NVAX unavailable / 5.12% |
| 2024-Q10/3 |
LoseNVAX / S&P -0.42% / 10.56% |
LoseNVAX / S&P -26.66% / 5.71% |
LoseNVAX / S&P NVAX unavailable / 5.59% |
| 2023-Q40/3 |
LoseNVAX / S&P -33.70% / 11.69% |
LoseNVAX / S&P -50.36% / 6.81% |
LoseNVAX / S&P NVAX unavailable / 7.78% |
| 2023-Q31/3 |
WinNVAX / S&P -2.56% / -3.27% |
LoseNVAX / S&P -43.15% / 7.52% |
LoseNVAX / S&P NVAX unavailable / -5.03% |
| 2023-Q21/3 |
LoseNVAX / S&P 7.22% / 8.74% |
WinNVAX / S&P 23.74% / 9.50% |
LoseNVAX / S&P NVAX unavailable / -8.57% |
| 2023-Q10/3 |
LoseNVAX / S&P -32.59% / 7.50% |
LoseNVAX / S&P -3.15% / 10.77% |
LoseNVAX / S&P NVAX unavailable / -15.69% |
| 2022-Q41/3 |
LoseNVAX / S&P -43.52% / 7.56% |
WinNVAX / S&P 72.89% / 11.88% |
LoseNVAX / S&P NVAX unavailable / -17.99% |
| 2022-Q31/3 |
LoseNVAX / S&P -64.61% / -4.88% |
WinNVAX / S&P 53.41% / 13.47% |
LoseNVAX / S&P NVAX unavailable / -1.41% |
| 2022-Q20/3 |
LoseNVAX / S&P -30.17% / -16.10% |
LoseNVAX / S&P 9.22% / 13.71% |
LoseNVAX / S&P NVAX unavailable / 11.04% |
| 2022-Q11/3 |
LoseNVAX / S&P -48.52% / -4.60% |
WinNVAX / S&P 52.59% / 15.97% |
LoseNVAX / S&P NVAX unavailable / 42.23% |
| 2021-Q41/3 |
LoseNVAX / S&P -30.99% / 11.03% |
WinNVAX / S&P 141.02% / 15.00% |
LoseNVAX / S&P NVAX unavailable / 96.40% |
| 2021-Q31/3 |
LoseNVAX / S&P -2.36% / 0.58% |
WinNVAX / S&P 487.90% / 10.77% |
LoseNVAX / S&P NVAX unavailable / 69.42% |
| 2021-Q22/3 |
WinNVAX / S&P 17.10% / 8.55% |
WinNVAX / S&P 2252.66% / 6.58% |
LoseNVAX / S&P NVAX unavailable / 51.81% |
| 2021-Q12/3 |
WinNVAX / S&P 62.60% / 6.17% |
WinNVAX / S&P 4991.93% / -1.06% |
LoseNVAX / S&P NVAX unavailable / 7.39% |
| 2020-Q41/3 |
LoseNVAX / S&P 2.92% / 12.15% |
WinNVAX / S&P 2448.48% / -3.72% |
LoseNVAX / S&P NVAX unavailable / -33.42% |
| 2020-Q32/3 |
WinNVAX / S&P 29.99% / 8.93% |
WinNVAX / S&P 1181.88% / -2.04% |
LoseNVAX / S&P NVAX unavailable / -27.10% |
| 2020-Q22/3 |
WinNVAX / S&P 513.77% / 20.54% |
WinNVAX / S&P 136.96% / -0.46% |
LoseNVAX / S&P NVAX unavailable / -27.11% |
| 2020-Q11/3 |
WinNVAX / S&P 241.21% / -19.60% |
LoseNVAX / S&P -36.90% / 3.47% |
LoseNVAX / S&P NVAX unavailable / -14.75% |
| 2019-Q40/3 |
LoseNVAX / S&P -20.72% / 9.07% |
LoseNVAX / S&P -45.57% / 5.36% |
LoseNVAX / S&P NVAX unavailable / 2.99% |
| 2019-Q30/3 |
LoseNVAX / S&P -14.33% / 1.70% |
LoseNVAX / S&P -58.59% / 5.02% |
LoseNVAX / S&P NVAX unavailable / 0.21% |
| 2019-Q20/3 |
LoseNVAX / S&P -46.73% / 4.30% |
LoseNVAX / S&P -45.90% / 6.64% |
LoseNVAX / S&P NVAX unavailable / 8.65% |
| 2019-Q10/3 |
LoseNVAX / S&P -70.11% / 13.65% |
LoseNVAX / S&P -18.58% / 8.12% |
LoseNVAX / S&P NVAX unavailable / 14.29% |
| 2018-Q42/3 |
WinNVAX / S&P -2.13% / -13.52% |
WinNVAX / S&P 9.98% / 9.05% |
LoseNVAX / S&P NVAX unavailable / 18.23% |
| 2018-Q32/3 |
WinNVAX / S&P 40.30% / 7.71% |
WinNVAX / S&P 47.43% / 10.21% |
LoseNVAX / S&P NVAX unavailable / 19.06% |
| 2018-Q21/3 |
LoseNVAX / S&P -36.19% / 3.43% |
WinNVAX / S&P 86.25% / 9.03% |
LoseNVAX / S&P NVAX unavailable / 14.46% |
| 2018-Q12/3 |
WinNVAX / S&P 69.35% / -0.76% |
WinNVAX / S&P 109.03% / 7.68% |
LoseNVAX / S&P NVAX unavailable / 12.46% |
| 2017-Q42/3 |
WinNVAX / S&P 8.77% / 6.64% |
WinNVAX / S&P 103.06% / 7.03% |
LoseNVAX / S&P NVAX unavailable / 13.82% |
| 2017-Q31/3 |
LoseNVAX / S&P -0.87% / 4.48% |
WinNVAX / S&P 65.52% / 5.68% |
LoseNVAX / S&P NVAX unavailable / 17.57% |
| 2017-Q21/3 |
LoseNVAX / S&P -10.16% / 3.09% |
WinNVAX / S&P 10.16% / 4.83% |
LoseNVAX / S&P NVAX unavailable / 17.74% |
| 2017-Q10/3 |
LoseNVAX / S&P 1.59% / 6.07% |
LoseNVAX / S&P -45.03% / 3.67% |
LoseNVAX / S&P NVAX unavailable / 13.32% |
| 2016-Q40/3 |
LoseNVAX / S&P -39.42% / 3.82% |
LoseNVAX / S&P -57.65% / 2.09% |
LoseNVAX / S&P NVAX unavailable / 7.05% |
| 2016-Q30/3 |
LoseNVAX / S&P -71.39% / 3.85% |
LoseNVAX / S&P -57.42% / 0.20% |
LoseNVAX / S&P NVAX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | NVAX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 24.03% | 20.78% |
| Annualized return | 24.03% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | NVAX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.32% | 83.14% |
| Annualized return | -48.35% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | NVAX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -93.21% | 319.30% |
| Annualized return | -23.58% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |